U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38 books (193 items)

1.
PDQ Cancer Information Summaries [Internet].

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Table of Contents

2.
Addendum to Haematological Cancers: improving outcomes (update).

Addendum to Haematological Cancers: improving outcomes (update).

National Collaborating Centre for Cancer (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 May.

Table of Contents

3.
Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.

Table of Contents

4.
Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Table of Contents

5.
Selinexor (Xpovio): CADTH Reimbursement Recommendation: Indication: Multiple myeloma [Internet].

Selinexor (Xpovio): CADTH Reimbursement Recommendation: Indication: Multiple myeloma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.

Table of Contents

6.
Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].

Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Table of Contents

7.
WHO Guidelines for Indoor Air Quality: Selected Pollutants.

WHO Guidelines for Indoor Air Quality: Selected Pollutants.

Geneva: World Health Organization; 2010.

Table of Contents

8.
Non-Hodgkin's Lymphoma: Diagnosis and Management.

Non-Hodgkin's Lymphoma: Diagnosis and Management.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)

Table of Contents

9.
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.

Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.

Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)

Table of Contents

10.
WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.

WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.

Geneva: World Health Organization; 2018.

Table of Contents

11.
Non-Alcoholic Fatty Liver Disease: Assessment and Management.

Non-Alcoholic Fatty Liver Disease: Assessment and Management.

National Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 49.)

Table of Contents

12.
Daratumumab (Darzalex SC): CADTH Reimbursement Recommendation: Indication: In combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis [Internet].

Daratumumab (Darzalex SC): CADTH Reimbursement Recommendation: Indication: In combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Table of Contents

13.
Spinal metastases and metastatic spinal cord compression.

Spinal metastases and metastatic spinal cord compression.

London: National Institute for Health and Care Excellence (NICE); 2023 Sep 6. (NICE Clinical Guidelines, No. 234.)

Table of Contents

14.
Myeloma: diagnosis and management.

Myeloma: diagnosis and management.

London: National Institute for Health and Care Excellence (NICE); 2018 Oct. (NICE Guideline, No. 35.)

Table of Contents

15.
Multimorbidity: Assessment, Prioritisation and Management of Care for People with Commonly Occurring Multimorbidity.

Multimorbidity: Assessment, Prioritisation and Management of Care for People with Commonly Occurring Multimorbidity.

National Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 Sep. (NICE Guideline, No. 56.)

Table of Contents

16.
Addendum to Clinical Guideline 164, Familial breast cancer.

Addendum to Clinical Guideline 164, Familial breast cancer.

London: National Institute for Health and Care Excellence (NICE); 2017 Mar. (Clinical Guideline Addendum, No. 164.1.)

Table of Contents

17.
Haematological cancers: improving outcomes.

Haematological cancers: improving outcomes.

London: National Institute for Health and Care Excellence (NICE); 2016 May 25. (NICE Guideline, No. 47.)

Table of Contents

18.
CADTH Canadian Drug Expert Committee Recommendation: Letermovir (Prevymis — Merck Canada Inc.): Indication: Cytomegalovirus infection, prophylaxis [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Letermovir (Prevymis — Merck Canada Inc.): Indication: Cytomegalovirus infection, prophylaxis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun.

Table of Contents

19.
Fostamatinib (Tavalisse): CADTH Reimbursement Recommendation: Indication: For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments [Internet].

Fostamatinib (Tavalisse): CADTH Reimbursement Recommendation: Indication: For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.

Table of Contents

20.
Osteoporosis: assessing the risk of fragility fracture.

Osteoporosis: assessing the risk of fragility fracture.

London: National Institute for Health and Care Excellence (NICE); 2017 Feb. (NICE Clinical Guidelines, No. 146.)

Table of Contents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...